Alzheimer's disease-related biomarkers and cancer-related cognitive decline: the thinking and living with cancer study.

Journal

Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089

Informations de publication

Date de publication:
24 May 2024
Historique:
received: 19 01 2024
revised: 22 04 2024
accepted: 15 05 2024
medline: 25 5 2024
pubmed: 25 5 2024
entrez: 24 5 2024
Statut: aheadofprint

Résumé

We evaluated whether plasma Alzheimer's Disease (AD)-related biomarkers were associated with cancer-related cognitive decline (CRCD) among older breast cancer survivors. We included survivors 60-90 years with primary stage 0-III breast cancers (n = 236) and frequency-matched non-cancer controls (n = 154) who passed a cognitive screen and had banked plasma specimens. Participants were assessed at baseline (pre-systemic therapy) and annually for up to 60-months. Cognition was measured using tests of attention, processing speed and executive function (APE) and learning and memory (LM); perceived cognition was measured by the FACT-Cog PCI. Baseline plasma neurofilament light (NfL), glial fibrillary acidic protein (GFAP), beta-amyloid 42/40 (Aβ42/40) and phosphorylated tau (p-tau181) were assayed using single molecule arrays. Mixed models tested associations between cognition and baseline AD-biomarkers, time, group (survivor vs control) and their two- and three-way interactions, controlling for age, race, WRAT4 Word Reading score, comorbidity and BMI; two-sided 0.05 p-values were considered statistically significant. There were no group differences in baseline AD-related biomarkers except survivors had higher baseline NfL levels than controls (p = .013). Survivors had lower adjusted longitudinal APE than controls starting from baseline and continuing over time (p = <0.002). However, baseline AD-related biomarker levels were not independently associated with adjusted cognition over time, except controls had lower APE scores with higher GFAP levels (p = .008). The results do not support a relationship between baseline AD-related biomarkers and CRCD. Further investigation is warranted to confirm the findings, test effects of longitudinal changes in AD-related biomarkers and examine other mechanisms and factors affecting cognition pre-systemic therapy.

Identifiants

DOI: 10.1093/jnci/djae113 PMID: 38788675
pubmed: 38788675
pii: 7681887
doi: 10.1093/jnci/djae113
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Jeanne Mandelblatt (J)

Georgetown Lombardi Institute for Cancer and Aging Research, Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington, DC, USA.
ORCID: 0000-0002-2490-005X

Jeffrey L Dage (JL)

Stark Neurosciences Research Institute, Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA.

Xingtao Zhou (X)

Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, DC, USA.

Brent J Small (BJ)

School of Aging Studies, University of South Florida, and Health Outcomes and Behavior Program, Moffitt Cancer Center, Tampa, FL, USA.

Tim A Ahles (TA)

Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Jaeil Ahn (J)

Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, DC, USA.

Ashley Artese (A)

Department of Exercise Science and Health Promotion, Charles E. Schmidt College of Science, Florida Atlantic University, Boca Raton, FL, USA.

Traci N Bethea (TN)

Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington, DC, USA.

Elizabeth C Breen (EC)

Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry & Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.
Cousins Center for Psychoneuroimmunology, University of California, Los Angeles, Los Angeles, CA, USA.

Judith E Carroll (JE)

Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry & Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.
Cousins Center for Psychoneuroimmunology, University of California, Los Angeles, Los Angeles, CA, USA.

Harvey J Cohen (HJ)

Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, NC, USA.

Martine Extermann (M)

Senior Adult Oncology Program, Department of Oncology, Moffitt Cancer Center, University of South Florida, Tampa, FL, USA.

Deena Graham (D)

John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.

Claudine Isaacs (C)

Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington, DC, USA.

Heather S L Jim (HSL)

Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA.

Brenna C Mcdonald (BC)

Department of Radiology and Imaging Sciences, Melvin and Bren Simon Comprehensive Cancer Center, and Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, USA.

Zev M Nakamura (ZM)

Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Sunita K Patel (SK)

City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

G William Rebeck (GW)

Department of Neuroscience, Georgetown University, Washington, DC, USA.

Kelly E Rentscher (KE)

Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.

James C Root (JC)

Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Kristen A Russ (KA)

Department of Medical and Molecular Genetics and National Centralized Repository for Alzheimer's and Related Dementias, Indiana University School of Medicine, Indianapolis, IN, USA.

Danielle B Tometich (DB)

Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA.

R Scott Turner (RS)

Department of Neurology, Georgetown University, Washington, DC, USA.

Kathleen Van Dyk (K)

Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry & Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.
Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA.

Wanting Zhai (W)

Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, DC, USA.

Li-Wen Huang (LW)

Division of Hematology/Oncology, University of California San Francisco and San Francisco Veterans Affairs Medical Center, USA.

Andrew J Saykin (AJ)

Department of Radiology and Imaging Sciences, Melvin and Bren Simon Comprehensive Cancer Center, and Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, USA.

Classifications MeSH